IMW 2019 | An MRD discussion: when, who and how
Faith Davies, Maria-Victoria Mateos and Nikhil Munshi
• 14 Sep 2019
Maria-Victoria Mateos, MD, PhD from University Hospital of Salamanca, Salamanca, Spain, Nikhil Munshi, MD, from Dana-Farber Cancer Institute, Boston, MA and Faith Davies, MBBCh, MRCP, MD, FRCPath, from NYU Langone Medical Center, New York, NY, discuss their views on which patients should undergo measurable residual disease (MRD) testing, at what time points testing should be carried out and how MRD should be tested. This interview took place at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
